357 related articles for article (PubMed ID: 12510195)
1. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
Hergovich A; Lisztwan J; Barry R; Ballschmieter P; Krek W
Nat Cell Biol; 2003 Jan; 5(1):64-70. PubMed ID: 12510195
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
6. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
7. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
8. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations.
Kishida T; Stackhouse TM; Chen F; Lerman MI; Zbar B
Cancer Res; 1995 Oct; 55(20):4544-8. PubMed ID: 7553625
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumour suppressor protein: new perspectives.
Ohh M; Kaelin WG
Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.
Maher ER; Webster AR; Richards FM; Green JS; Crossey PA; Payne SJ; Moore AT
J Med Genet; 1996 Apr; 33(4):328-32. PubMed ID: 8730290
[TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
12. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
14. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
[TBL] [Abstract][Full Text] [Related]
15. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.
Zatyka M; Morrissey C; Kuzmin I; Lerman MI; Latif F; Richards FM; Maher ER
J Med Genet; 2002 Jul; 39(7):463-72. PubMed ID: 12114475
[TBL] [Abstract][Full Text] [Related]
16. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
Richards FM; Schofield PN; Fleming S; Maher ER
Hum Mol Genet; 1996 May; 5(5):639-44. PubMed ID: 8733131
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.
Li Z; Na X; Wang D; Schoen SR; Messing EM; Wu G
J Biol Chem; 2002 Feb; 277(7):4656-62. PubMed ID: 11739384
[TBL] [Abstract][Full Text] [Related]
18. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
19. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
20. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]